论文部分内容阅读
目的观察对比联合莫西沙星与联合左氧氟沙星治疗复治耐多药肺结核的疗效及安全性。方法采用随机分组的方法将138名复治耐多药肺结核患者分成治疗组(T组)69例,对照组(C组)69例,治疗组选用联合莫西沙星方案,对照组选用联合左氧氟沙星方案。结果治疗2个月以上痰菌阴转率治疗组明显优于对照组,两者差异有统计学意义(P<0.05)。不良反应发生率治疗组与对照组差异无统计学意义(P>0.05)。结论莫西沙星是一种安全、有效的抗结核药物,方案中联合莫西沙星较左氧氟沙星效果更好。
Objective To observe the efficacy and safety of the combination of moxifloxacin and levofloxacin in the treatment of multi-drug resistant pulmonary tuberculosis. Methods A total of 138 patients with multi-drug resistant pulmonary tuberculosis were divided into treatment group (group T), 69 cases (control group), group C (69 cases), treatment group combined with moxifloxacin program, and control group . Results The treatment of sputum negative conversion rate over 2 months was significantly better than the control group, the difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the treatment group and the control group (P> 0.05). Conclusion Moxifloxacin is a safe and effective antituberculosis drug, and the combination of moxifloxacin and levofloxacin is better than that of levofloxacin.